ARTICLE | Emerging Company Profile
Pheast: Forty Seven founders reunite for precision macrophage combos
Backed by Catalio and Arch, start-up from Forty Seven founders aims to target patient-specific ‘don’t eat me’ signals beyond CD47
May 10, 2022 12:12 AM UTC
Pheast is developing cancer combination therapies that include a component targeting the latest “don’t eat me” signal: CD24.
The macrophage checkpoint has overlapping but distinct expression and activation patterns from CD47, the checkpoint Pheast Therapeutics Inc.’s founders pursued at their former company Forty Seven Inc., which means CD24 could find utility in different cancers. ...
BCIQ Target Profiles